Clinical Trials · NCT02366247
Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrollment
- 463
- Start date
- Aug 2013
- Locations
- 32 sites, China
- Primary endpoint
- Loss of HBeAg